Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - film coated tablets - amoxicillin as trihydrate 500 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children :• acute bacterial sinusitis (adequately diagnosed)• acute otitis media • acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - amoxicillin as trihydrate 600 mg / 5 ml; clavulanic acid as potassium salt 42.9 mg / 5 ml - amoxicillin and enzyme inhibitor - augmentin es is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant streptococcus pneumoniae:consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - amoxicillin as trihydrate 600 mg / 5 ml; clavulanic acid as potassium salt 42.9 mg / 5 ml - amoxicillin and enzyme inhibitor - augmentin es is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant streptococcus pneumoniae:consideration should be given to official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 1000 mg - augmentin xr extended release tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., h. influenzae , m. catarrhalis , h. parainfluenzae , k. pneumoniae , or methicillin-susceptible s. aureus ) and s. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin mics = 2 mcg/ml). augmentin xr is not indicated for the treatment of infections due to s. pneumoniae with penicillin mics ≥ 4 mcg/ml. data are limited with regard to infections due to s. pneumoniae with penicillin mics ≥ 4 mcg/ml (see clinical studies). of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age > 65 years was studied. patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied. in patients with community-acquire

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate eqv amoxycillin; potassium clavulanate eqv clavulanic acid - tablet, film coated - 500 mg - amoxycillin trihydrate eqv amoxycillin 500 mg; potassium clavulanate eqv clavulanic acid 125 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 1004.43mg eqv amoxycillin; potassium clavulanate 148.91mg eqv clavulanic acid - tablet, film coated - 875 mg - amoxycillin trihydrate 1004.43mg eqv amoxycillin 875 mg; potassium clavulanate 148.91mg eqv clavulanic acid 125 mg

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 250 mg - augmentin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: − caused by β-lactamase−producing strains of h. influenzae and m. catarrhalis . − caused by β-lactamase−producing strains of h. influenzae and m. catarrhalis . − caused by β-lactamase−producing strains of h. influenzae and m. catarrhalis . − caused by β-lactamase−producing strains of s. aureus , e. coli , and klebsiella spp. − caused by β-lactamase−producing strains of e. coli , klebsiella  spp., and enterobacter spp. while augmentin is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with augmentin due to its amoxicillin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase−producing organisms susceptible to augmentin should not require the addition of another antibiotic. because amoxicillin has greater in vitro activity again

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxycillin; clavulanic acid -

United States - English - NLM (National Library of Medicine)

usantibiotics, llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - augmentin es-600 is indicated for the treatment of pediatric patients with - recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics less than or equal to 2 mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors:      - antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) daycare attendance [s ee microbiology (12.4) ]. limitations of use acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. augmentin es-600 is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic greater than or equal to 4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both s. pneumoniae (penicillin mic less than or equal to 2 mcg/ml) and the

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 229.58mg/5ml eqv amoxycillin; potassium clavulanate 33.95mg/5ml eqv clavulanic acid - powder, for suspension - 200 mg/5 ml - amoxycillin trihydrate 229.58mg/5ml eqv amoxycillin 200 mg/5 ml; potassium clavulanate 33.95mg/5ml eqv clavulanic acid 28.5 mg/5 ml